Chronic obstructive pulmonary disease and congestive heart failure: iarc-icpms. Three clinical applications of the human gene: a narrative literature review of comorbidity, pathophysiology, diagnosis, and management
Chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) are among the leading causes of morbidity and mortality in the world. The high comorbidity burden presents important clinical challenges in exacerbating the issues of diagnosis and treatment due to overlapping symptom profiles, shared risk factors, and interconnected pathophysiological processes. This narrative review summarizes recent evidence on the epidemiology, pathophysiology, diagnostic challenges and therapeutic strategies for these patients. Peer-reviewed studies were identified by conducting a systematic search of PubMed, MEDLINE, and EMBASE from 2016 to 2024. Existing data suggests that COPD occurs in 20–30\% of patients with CHF, and a comparable proportion of moderate-to-severe COPD has left ventricular dysfunction. Coginitive impairment is an independent predictor of adverse clinical outcomes, including higher rates of hospitalization and mortality. Systemic inflammation, oxidative stress, skeletal muscle dysfunction and neurohormonal activation are shared pathways linking these different diseases. Differential diagnosis is limited because of clinical symptom overlap; however, each mentioned biomarker has complementary diagnostic utility in general: natriuretic peptides will identify pulmonary hypertension due to left heart failure, echocardiography can assess underlying structural heart disease and pulmonary function testing helps characterize the underlying pathology. Management should be a personalized and multi-faceted approach focusing on drug safety related to beta-blockers and bronchodilators along with non-pharmacologic strategies such as pulmonary rehabilitation and cardiac rehabilitation. This review underscores the need for joint clinical assessment and supports more prospective studies of this high-risk group.
Сведения
- Опубликовано
- 2026 · Т. 5, № 1, С. 21-31
- Язык
- Английский
- ISSN
- 2181-3612
- Издатель
- Andijan State Medical Institute